Pharmaceutical drugs #specialty #pharma

Posted On Oct 29 2016 by

#pharmaceutical drugs # Erelzi Erelzi (etanercept-szzs) is a tumor necrosis factor (TNF) blocker biosimilar to Enbrel indicated for the treatment of rheumatoid arthritis. Troxyca ER Troxyca ER (oxycodone hydrochloride and naltrexone hydrochloride) is an extended-release, abuse-deterrent, narcotic analgesic formulation. Sustol Sustol (granisetron) is a long-acting 5-HT3 antagonist indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV). Drugs in Development (Not yet approved) Ingrezza Ingrezza (valbenazine) is a novel, highly-selective VMAT2 inhibitor in development for the treatment of tardive dyskinesia. brigatinib Brigatinib is an investigational anaplastic lymphoma kinase (ALK) inhibitor in development for the treatment of patients with anaplastic. Radicava …

What are some of the commonly abused prescription drugs? #pharmaceutical #companies #jobs

Posted On Oct 29 2016 by

#pharmaceutical drugs # Prescription Drug Abuse Although many medications can be abused, the following three classes are most commonly abused: Opioids—usually prescribed to treat pain; Central nervous system (CNS) depressants—used to treat anxiety and sleep disorders; and Stimulants—most often prescribed to treat attention deficit hyperactivity disorder (ADHD). This page was last updated November 2014 Contents Ordering Publications Get this Publication Featured Publications ​Research Reports This series of reports simplifies the science of research findings for the educated lay public, legislators, educational groups, and practitioners. The series reports on research findings of national interest.

Generic Pharmaceutical Manufacturing, Generic Drugs – Lannett Company

Posted On Oct 28 2016 by

#pharmaceutical manufacturing companies # About Us Founded in 1942, Lannett develops, manufactures and distributes generic prescription pharmaceutical products in tablet, capsule and oral liquid forms to customers throughout the United States. Lannett markets its products primarily to drug wholesalers, retail drug chains, distributors, and government agencies. We employ a staff of dedicated people who work together to produce drug products that sick people can afford to buy that will treat their illness, make them well, reduce suffering and improve the quality of their lives. Arthur Bedrosian interview on Fox Business � Mornings with Maria .See the video here We are …

5 best-paying jobs in drugs and pharmaceuticals industry #purdue #pharmaceutical

Posted On Oct 27 2016 by

#jobs in the pharmaceutical industry # 5 best-paying jobs in drugs and pharmaceuticals industry Drugs and pharmaceutical industry sales are projected to grow 5.1 percent annually to 2020, when worldwide sales will reach the trillion dollar mark, according to the 2015 Pharm Science Strategic Outlook. Specialty and biologic drugs will make up more than half of industry sales by 2020 and therapeutic vaccines are also a significant new opportunity. Here are five of the best-paying jobs in the drugs and pharmaceutical industry. Biotechnology Senior Research Scientist | Median Annual Salary: $98,527 Salary outlook: B iotechnology s enior research scientists assess …

Pharmaceutical Packaging – Packaging Solutions for Drugs #industry #pharmacy

Posted On Oct 26 2016 by

#pharma packaging solutions # A Drug is Only as Good as its Packaging Permits How secure are your packaging materials? In recent years, the pharmaceutical industry has been developing drugs that are increasingly sensitive. In order to protect these active ingredients. pharmaceutical packaging requirements were consistently increasing, too. Thanks to our comprehensive material and process expertise we develop packaging solutions for you that are individually tailored to the drug. We can thus offer your products optimal protection. The added value accruing from RAUMEDIC RAUMEDIC develops polymeric packaging solutions and expands them through individual functions that are tailored to your drug. …

Pharma Giant Eli Lilly Wants to Launch 20 New Drugs by 2023 #pharma #recruiters

Posted On Oct 25 2016 by

#lilly pharma # Pharma Giant Eli Lilly Wants to Launch 20 New Drugs by 2023 Indianapolis-based pharmaceutical giant Eli Lilly lly laid out an ambitious R D agenda for launching up to 20 new drugs by 2023 during an investor presentation on Tuesday. The company also said it hopes to add a significant number of uses for its existing therapies in order to bolster those drugs market strength. Lilly said that it would be focusing on key franchises such as diabetes, oncology, and neurodegenerative diseases like Alzheimer s and add immunology to its roster of core therapeutic spaces. In addition, …

Understanding Generic Drugs #pharma #logo

Posted On Oct 23 2016 by

#generic pharmaceutical # Understanding Generic Drugs Generic drugs are important options that allow greater access to health care for all Americans. They are copies of brand-name drugs and are the same as those brand name drugs in dosage form, safety, strength, route of administration, quality, performance characteristics and intended use. Health care professionals and consumers can be assured that FDA approved generic drug products have met the same rigid standards as the innovator drug. All generic drugs approved by FDA have the same high quality, strength, purity and stability as brand-name drugs. And, the generic manufacturing, packaging, and testing sites …

Drug Channels: 2013 Pharmacy Market Share for Specialty Drugs – and the Biggest Players #pharmaceutical #companies #in #new #york

Posted On Oct 23 2016 by

#pharmaceutical companies market share # Our research shows a booming market: In 2013, retail, mail, and specialty pharmacies dispensed about $63 billion in specialty pharmaceuticals. Specialty drugs accounted for 22% of total pharmacy industry revenues. Three companies Express Scripts, CVS Caremark, and Walgreens accounted for 63% of revenues from pharmacy-dispensed specialty drugs. The next three largest players had a combined share of about 5%. Read on for our market share estimates for the top players, observations on the market’s structure, and details of my panel discussion with specialty pharmacy leaders at next week s sPCMA Business Forum . THE NOMINEES …

Novartis splits drugs business into two, pharma chief to leave #pure #pharma

Posted On Oct 23 2016 by

#novartis pharma # Novartis splits drugs business into two, pharma chief to leave By John Miller and Ben Hirschler | ZURICH/LONDON ZURICH/LONDON (Reuters) – Novartis is splitting its pharmaceuticals division into two business units, one focused on cancer and the second on other drugs, while switching out its current pharma head in the second high-profile management reshuffle this year. David Epstein, the American head of Novartis Pharmaceuticals and a 27-year veteran with the group, will leave the company to “explore new challenges from the U.S.”, Novartis said. Epstein’s re-location to the United States implies he is not in the running …

The top 10 most expensive drugs of 2013 #aspenbio #pharma

Posted On Oct 23 2016 by

#pharmaceutical companies news # The top 10 most expensive drugs of 2013 The price of Gilead Sciences’ breakthrough drug Sovaldi has drawn all of the attention this year. By pricing it at $85,000 for a 12-week course, Gilead Sciences ($GILD) has been pilloried by politicians, payers and providers. But as EvaluatePharma points out, at that price Sovaldi barely makes it into the top 20 most expensive drugs. number 19 to be exact, just above Novartis’ ($NVS) Gleevec and just below GlaxoSmithKline’s ($GSK) Mekinist. Sovaldi is pricey, but if you want to talk about really pricey, then look at the 10 …